北京時(shí)間11月5日凌晨消息，美國(guó)司法部周一宣布，強(qiáng)生(93.03, -0.34, -0.36%)公司(JNJ)已同意支付22億美元，以了結(jié)有關(guān)其向醫(yī)生和藥房提供回扣，以及非法營(yíng)銷藥物用于未經(jīng)批準(zhǔn)用途的刑事和民事調(diào)查。
此次和解牽涉到強(qiáng)生及其子公司楊森制藥，涉及的藥物包括精神分裂癥治療藥物Risperd，抗精神病藥物Invega，以及心臟病藥物Natrecor。
在總計(jì)22億美元的罰款當(dāng)中，有17.2億美元是支付給美國(guó)聯(lián)邦和州政府的民事和解金，另有4.85億美元是刑事罰款和沒收利潤(rùn)。
Risperdal是由楊森制藥負(fù)責(zé)銷售的，據(jù)消息人士稱，楊森預(yù)計(jì)將承認(rèn)錯(cuò)誤標(biāo)簽的輕罪指控。
CNN的報(bào)道
Health care manufacturer Johnson & Johnson and its subsidiaries will pay more than $2.2 billion to resolve criminal and civil investigations over allegations that they marketed three drugs for uses that were never approved, U.S. Attorney General Eric Holder said Monday in Washington.
The settlements also cover claims that the companies gave "kickbacks" to physicians and to nursing home pharmacies to promote the drugs' usage.
The claims involve the schizophrenia drugs Risperdal and Invega and the heart-failure drug Natrecor.
Holder said Johnson & Johnson improperly marketed Risperdal for treatment of psychotic symptoms in elderly, non-schizophrenic patients, even though the drug was approved to treat only schizophrenia.
He said Risperdal and Invega also were improperly marketed for dementia treatment.
That led insurance companies to pay for claims they never should have been paying, he said.
The companies "lined their pockets at the expense of American taxpayers (and) patients," Holder said.
Natrecor was marketed as a treatment for patients with less severe heart failure than mentioned in its Food and Drug Administration approval, according to the Department of Justice.
